CYBN Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to Cybin, Inc.'s net margin of 42.95%. Cybin, Inc.'s return on equity of -53.73% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

Cybin, Inc. has a consensus price target of $47.04, signalling upside risk potential of 558%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 3.01%. Given that Cybin, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Cybin, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..

Cybin, Inc. has a beta of 1.083, which suggesting that the stock is 8.259% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

Cybin, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cybin, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cybin, Inc. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Cybin, Inc.'s net income of -$33.7M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Cybin, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 28.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cybin, Inc. is -- versus 8.59x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Edesa Biotech, Inc. has a net margin of -- compared to Cybin, Inc.'s net margin of --. Cybin, Inc.'s return on equity of -53.73% beat Edesa Biotech, Inc.'s return on equity of -77.48%.

Cybin, Inc. has a consensus price target of $47.04, signalling upside risk potential of 558%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 643.24%. Given that Edesa Biotech, Inc. has higher upside potential than Cybin, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Cybin, Inc..

Cybin, Inc. has a beta of 1.083, which suggesting that the stock is 8.259% more volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Cybin, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cybin, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Cybin, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Cybin, Inc.'s net income of -$33.7M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Cybin, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cybin, Inc. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of -- compared to Cybin, Inc.'s net margin of -2178.51%. Cybin, Inc.'s return on equity of -53.73% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

Cybin, Inc. has a consensus price target of $47.04, signalling upside risk potential of 558%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 815.44%. Given that Lexaria Bioscience Corp. has higher upside potential than Cybin, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Cybin, Inc..

Cybin, Inc. has a beta of 1.083, which suggesting that the stock is 8.259% more volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

Cybin, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cybin, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Cybin, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of $174K. Cybin, Inc.'s net income of -$33.7M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Cybin, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cybin, Inc. is -- versus 14.86x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -- compared to Cybin, Inc.'s net margin of --. Cybin, Inc.'s return on equity of -53.73% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Cybin, Inc. has a consensus price target of $47.04, signalling upside risk potential of 558%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 449.6%. Given that Cybin, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe Cybin, Inc. is more attractive than Oncolytics Biotech, Inc..

Cybin, Inc. has a beta of 1.083, which suggesting that the stock is 8.259% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Cybin, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cybin, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Cybin, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Cybin, Inc.'s net income of -$33.7M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Cybin, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cybin, Inc. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.